Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses a new 0.3% tretinoin topical launched by MinoxidilMax for mixing with other solutions, with some users expressing concern about potential skin irritation compared to lower concentrations. MinoxidilMax has also released other products like topical Dutasteride and RU58841.

The user is considering adding a topical treatment to their current regimen of finasteride and oral minoxidil to protect their temple area, with options like piro, RU58841, or topical finasteride or dutasteride. They are advised against overcomplicating their treatment, but another user suggests a topical with 8% minoxidil/dutasteride for better results.

A 30-year-old woman with androgenetic alopecia is considering bicalutamide to slow hair loss but is concerned about its impact on muscle growth due to its anti-androgen effects. Alternatives suggested include dutasteride, spironolactone, RU58841, and minoxidil, with concerns about bicalutamide's side effects.

The conversation discusses hair loss treatments, including the use of 2.5mg Dutasteride, 1mg Finasteride, and Minoxidil 5%, with concerns about side effects like water retention and facial changes. The user is considering alternative Minoxidil applications, such as microneedling and sublingual Minoxidil, to minimize side effects.

A 27-year-old male is experiencing a recurring pattern of hair loss after 5 months of using oral minoxidil and finasteride, despite initial success. He is considering using topical androgen receptor blockers like RU58841, pyrilutamide, or clascoterone to address potential androgen receptor hypersensitivity.

ABS-201, a prolactin receptor blocker, shows promise in reversing hair loss and graying, with early success in macaques. Current treatments like finasteride, minoxidil, and RU58841 are still widely used, but new options like PP405 are eagerly anticipated.

A man in his 50s, who has been on Finasteride for 15 years, is considering adding a custom topical Minoxidil blend to his treatment due to recent hairline recession. He questions whether the custom blend is more effective than generic Minoxidil, expresses concerns about shedding and body hair growth, and seeks advice on application timing with styling products and whether to pursue other treatments like PRP or laser.

The user reports progress in hair regrowth using topical finasteride/minoxidil, microneedling, topical dutasteride, latanoprost, and MSM supplements. They express frustration over the lack of interaction on progress posts compared to trivial topics.

Topical finasteride (P-3074) can inhibit scalp DHT by up to 70%, with some users experiencing systemic absorption similar to oral use. Users discuss varying application frequencies and concentrations, with some noticing side effects when overused.

The user is using finasteride, HGH, GHK-CU, BPC-157, KPV, biotin/collagen/keratin vitamins, ketoconazole shampoo, and low-dose naltrexone to address hair loss, avoiding minoxidil due to past shedding experiences. Adenosine is discussed as a potential alternative to minoxidil, though it is noted to be expensive and hard to find.

OP is considering using Stemoxydine or the Ordinary Multi Peptide Hair Serum as a carrier for topical finasteride, avoiding minoxidil due to palpitations. They plan to crush finasteride pills into a 30 ml solution.

Extended-release oral minoxidil (VDPHL01) shows promising results for hair growth with improved safety, achieving significant hair count increases and minimal side effects compared to placebo. The treatment is designed to maintain effective concentrations while reducing side effects, making it a safer option for those who cannot tolerate standard minoxidil.

ET-02, a PAI-1 inhibitor, is not proven to be more effective than Minoxidil for hair loss. Other treatments like finasteride, dutasteride, PP405, and AMP-303 are also discussed, focusing on cellular senescence and oxidative stress.

PP405, a promising hair loss treatment, is expected to be available by 2027, with faster trials due to its topical nature. Users are eager for its release, comparing it to existing treatments like minoxidil and finasteride, but remain cautious about its long-term effectiveness.

Finding a topical solution for hair loss, with specific treatments mentioned such as Minoxidil, Finasteride and RU58841.

The conversation discusses various hair loss treatments, including minoxidil, finasteride, latanoprost, tretinoin, dutasteride, and cetirizine, with concerns about effectiveness, cost, and potential side effects. Users express skepticism about the product's price and the combination of multiple compounds.

A user on finasteride for hair loss is considering topical dutasteride to further reduce scalp DHT and is using various other topicals as substitutes for minoxidil due to concerns about the safety of their cats and potential heart side effects from oral minoxidil. They are exploring whether a once-weekly application of topical dutasteride would be effective.

The conversation discusses alternatives to 5AR inhibitors for hair loss treatment, suggesting options like minoxidil, KX-826, pyrilutimide, microneedling, and topical bicalutamide. Concerns about side effects and the effectiveness of these treatments are also highlighted.

A user is seeking feedback on a homemade topical finasteride formula for hair loss, consisting of 7.5 mg of finasteride, propylene glycol, ethanol, and distilled water. They aim to achieve a 0.0125% solution by applying 2 ml daily.

A user who was part of an ongoing trial for a prolactin blocker and had regrowth, but the progress photos were not shared due to negative reactions from other users. Treatments mentioned include HMI-115, Minoxidil, Finasteride, and RU58841.

A user discusses a topical treatment combining Minoxidil, Betamethasone Valerate, Canrenone, Finasteride, and Dutasteride for hair loss. The treatment is RX-only and provided by a dermatologist.

The conversation is about hair loss treatments, specifically Pyrludimide (KX-826) and Breezula (clascoterone), with the user unable to tolerate finasteride and dutasteride. The user plans to use these treatments alongside minoxidil, considering the efficacy and availability of each option.

Rapamycin and metformin may have hair regeneration properties. Specific treatments discussed include Minoxidil, finasteride, and RU58841.

The user is asking for opinions on whether their hair growth is due to Pantostin and hormone treatments. One commenter confirms regrowth and asks about the hormone treatments.

People are hopeful about future hair loss treatments like PP405, GT20029, and VDPHL01, while some are currently using finasteride and minoxidil. There is skepticism about the effectiveness of new treatments, and some advise against hair transplants until more promising drugs are available.

The user switched from Pyrilutamide to RU58841, changed their Minoxidil solution, and continued using low-dose Finasteride, derma rolling, and specific shampoo. They asked others about their plans after Pyrilutamide's disappointing results.

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

A user plans to create a custom topical solution by adding finasteride, caffeine, cetirizine, and melatonin to a minoxidil bottle, questioning the stability and effectiveness of this mix. Concerns include potential crystallization and solution muddiness with added ingredients.

The conversation discusses a study comparing microneedling combined with minoxidil versus biotin/panthenol for hair loss. Results suggest biotin/panthenol may be superior to minoxidil, though the sample size was small.

The conversation discusses the effectiveness of reducing DHT for hair loss treatment and explores alternative approaches like reducing androgen receptor sensitivity. Specific treatments mentioned include finasteride, dutasteride, pyrilutamide (KX-826), GT20029, and RU58841.